搜索结果
靶点ID:TCMBANKGE000106
靶点别名:FEPS2; Nav1.8; PN3; SNS; hPN3
靶点描述:sodium voltage-gated channel alpha subunit 10
染色体:3
染色体位置:3p22.2
靶点类型:protein-coding
HERB_ID:HBTAR003632
HGNC_Link:10582
OMIM_Link:604427
Ensembl_Link:ENSG00000185313
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000005 | tetrodotoxin | C11H17N3O8 | 319.27 g/mol | C(C1(C2C3C(N=C(NC34C(C1OC(C4O)(O2)O)O)N)O)O)O | |
| TCMBANKIN000015 | brefeldin a | (7S,15S,1R)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-o ne; AC1O5L8S; AKOS024282481; SR-01000597412-1; MolPort-004-955-162; NCGC00025061-02; UPCMLD-DP095:002; NCGC00025061-03; IDI1_033950; (2E,7S,10E,12R,13R,15S)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one; SR-01000597412; HMS1361J22; 1,6,7,8,9,11a?,12,13,14,14?a-Decahydro-1?,13?-dihydroxy-6?-methyl-4H-cyclopent(f)oxacyclotridecin-4-one; ST056354; UPCMLD-DP095; 4H-Cyclopent(f)oxacyclotridecin-4-one,1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-; LS-58416; CCG-208020; NSC-89671; NSC 56310; 1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent[f]oxacyclotridecin-4-one; (1R,6S,13S,14AR)-1,13-DIHYDROXY-6-METHYL-1H,6H,7H,8H,9H,11AH,12H,13H,14H,14AH-CYCLOPENTA[F]OXACYCLOTRIDECAN-4-ONE; HMS1989J22; 4H-Cyclopent(f)oxacyclotridecin-4-one, 1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-; NCGC00017254-03; CHEMBL1572153; HMS3402J22; HMS1791J22; UPCMLD-DP095:001; NCGC00017254-04; brefeldin A; Cyanaein; G405; 20350-15-6; SCHEMBL12648486; Cyanein; BSPBio_001480; Decumbin; (+)-Brefeldin A, Eupenicillium brefeldianum; C16H24O4 | C16H24O4 | 280.36 g/mol | CC1CCCC=CC2CC(CC2C(C=CC(=O)O1)O)O |
| TCMBANKIN002295 | Datumetine | datumetine | C16H21NO3 | 275.34 | CN1C2CCC1CC(C2)C3=C(C=CC(=C3)C(=O)O)OC |
| TCMBANKIN003384 | plumb | C14H22N2O | CCN(CC)CC(=O)NC1=C(C=CC=C1C)C | ||
| TCMBANKIN017120 | (E)-5-(4-hydroxy-3-methoxy-phenyl)-1-piperidino-pent-2-en-1-one | (E)-5-(4-hydroxy-3-methoxy-phenyl)-1-piperidin-1-yl-pent-2-en-1-one; (E)-5-(4-hydroxy-3-methoxy-phenyl)-1-(1-piperidyl)pent-2-en-1-one; (E)-5-(4-hydroxy-3-methoxyphenyl)-1-piperidin-1-ylpent-2-en-1-one; (E)-5-(4-hydroxy-3-methoxyphenyl)-1-(1-piperidyl)pent-2-en-1-one | C17H23NO3 | 289.4 g/mol | COC1=C(C=CC(=C1)CCC=CC(=O)N2CCCCC2)O |
| TCMBANKIN019913 | dl-3n-butylphthalide | (3R)-3-butyl-3H-isobenzofuran-1-one; (3R)-3-butyl-3H-2-benzofuran-1-one | C12H14O2 | 190.24 | |
| TCMBANKIN021672 | apoatropine | 1.alpha.H, atropate (ester), hydrobromide; Apoatropine, hydrobromide; 6020-16-2; DTXSID70635222; NSC-41796; 8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenylprop-2-enoate--hydrogen bromide (1/1); Benzeneacetic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, hydrobromide, endo-; NSC41796; Atropamine | C17H21NO2 | 271.35 | CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=CC=C3 |
| TCMBANKIN026109 | (3S)-3-butyl-3H-isobenzofuran-1-one | (3S)-3-butyl-3H-2-benzofuran-1-one | C12H14O2 | 190.24 | |
| TCMBANKIN036067 | vanadium | V | 50.941 g/mol | [V] | |
| TCMBANKIN041639 | flavone | GTPL409; HMS3604K19; 2-phenyl-4H-benzopyran-4-one; Flavone (VAN); 5-17-10-00552 (Beilstein Handbook Reference); 2-Phenylchrome; MEGxp0_001685; MLS002473400; NCGC00090962-04; SMR000112315; MLS002177804; MCULE-3856134714; 4H-1-Benzopyran-4-one, 2-phenyl-; BDBM50028962; FT-0603450; ZX-AFC000856; Flavone (VAN) (8CI); Phenylchromone; C10043; AIDS-051918; IDI1_016673; DSSTox_CID_2048; D08RVN; 2-Phenyl-chromen-4-one; VHBFFQKBGNRLFZ-UHFFFAOYSA-N; 46370_FLUKA; InChI=1/C15H10O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10; KS-000016AQ; Maybridge3_005286; ACM525826; AC1L1VPW; SBB072435; Asmacoril; CU-00000000060-1; 2-Phenylbenzopyran-4-one; I14-21772; S2V45N7G3B; BRD-K86741145-001-01-5; CBiol_000263; T667; HMS2269O06; KB-232056; ACon1_000055; MFCD00006825; F0015; Flavon; UNII-S2V45N7G3B; BIF1002; HMS1446A06; DB-052142; 2-PHENYLCHRONONE; 2-PHENYL- GAMMA-BENZOPYRONE; KB-174113; ZB002210; ZINC57674; A-8354; 2-Phenyl-4H-chromen-4-one #; 2-Phenylbenzo[b]pyran-4-one; ANW-75635; NCGC00090962-03; 46380_FLUKA; AIDS051918; CTK1G8239; NSC 19028; ZX-AT010673; LMPK12110097; STK164205; DB07776; CC-11825; L001213; TR-018648; ZINC00057674; LS-39844; CCRIS 4288; 4hki; CHEMBL275638; NCGC00090962-05; C15608; 2-phenyl-1-benzopyran-4-one; 2-Phenyl-4-benzopyron; 54849-74-0; F-2700; DSSTox_GSID_22048; CAS-525-82-6; Cromarile; 2-phenyl-4H-chromen-4-one; NSC-19028; BRN 0157598; SC-65147; NCGC00090962-06; bmse000945; AK324531; Cromaril; SCHEMBL18879; C-12398; F2003_SIAL; Flavone, Flavone; 2-Phenyl-4H-benzopyran-4-one; 2-Phenyl-4H-1-benzopyran-4-one; ICCB2_000263; 2-Phenyl-gamma-benzopyrone; 2-phenylchromen-4-one; 6CC153EB-39A6-42FC-BE96-C8BF1D585E27; NSC19028; DSSTox_RID_76467; Tox21_400059; OR1156; 2-Phenyl-4-chromone; DTXSID2022048; EINECS 208-383-8; 2-Phenyl-4H-chromen-4-one; Tox21_202987; ST45028199; FLAVONE; D0S0RK; A829155; FLN; 525-82-6; NCGC00090962-02; Chaste tree berry Extract; 11091-19-3; 2-phenyl-4-chromenone; 2-Phenyl-4H-chromen-4-on; CCG-214679; VA10914; 525F826; 2-Phenyl-.gamma.-benzopyrone; 2-Phenylchromone; Flavone; Chromocor; 4h-1-benzopyran-4-one,2-phenyl-; KB-191942; CHEBI:42491; ACMC-20aj2d; AKOS000603572; BG01525318; NCGC00168837-01; PubChem9849; Vitex agnus-castus; MLS002638647; BIDD:ER0515; ST5308279; MolPort-001-016-955; NCGC00090962-01; 66585-04-4; NCGC00260532-01 | C15H10O2 | 222.24 | C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2 |
| TCMBANKIN058547 | (2R)-flavanone | ZINC00058113; CHEBI:36105; (2R)-2-phenylchroman-4-one; (2R)-2-phenyl-2,3-dihydro-4H-chromen-4-one; (2R)-2-phenyl-4-chromanone | C15H12O2 | 224.25 | C1C(OC2=CC=CC=C2C1=O)C3=CC=CC=C3 |
| TCMBANKIN061321 | n-methyl-corypalline | C12H17NO2 | 207.27 g/mol | CN1CCC2=CC(=C(C=C2C1)OC)OC | |
| TCMBANKIN061617 | eugenol 4-Allyl-2-methoxyphenol | C10H12O2 | COC1=C(C=CC(=C1)CC=C)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000002 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Sign or Symptom | phenotype | |
| TCMBANKDI000074 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000802 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument | Finding | phenotype | |
| TCMBANKDI003957 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the cardiovascular system | Sign or Symptom | phenotype | |
| TCMBANKDI004384 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI004713 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI004857 | Nervous System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI005748 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI008259 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Finding | phenotype | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009702 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
| TCMBANKDI009943 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI011479 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI014368 | Pathological Conditions, Signs and Symptoms | - | Sign or Symptom | phenotype | |
| TCMBANKDI015435 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI015452 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI017238 | - | - | Diagnostic Procedure | phenotype | |
| TCMBANKDI018017 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Sign or Symptom | phenotype | |
| TCMBANKDI021784 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Cell or Molecular Dysfunction | phenotype | |
| TCMBANKDI022421 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI022746 | - | - | Diagnostic Procedure | phenotype | |
| TCMBANKDI023140 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI023791 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI023984 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI025401 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Pathologic Function | phenotype | |
| TCMBANKDI025850 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI026511 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027325 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Sign or Symptom | phenotype | |
| TCMBANKDI027872 | Cardiovascular Diseases | Abnormality of the cardiovascular system | Finding | phenotype | |
| TCMBANKDI028487 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI029038 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | - | Disease or Syndrome; Congenital Abnormality | disease | |
| TCMBANKDI029321 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI030316 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI032138 | Pathological Conditions, Signs and Symptoms | - | Pathologic Function | phenotype | |
| TCMBANKDI032513 | Cardiovascular Diseases | - | Disease or Syndrome | group |
滇IICP备16009434号-1 |
Dai SX Lab